Medibact GuidesShop at Medibact

Stacking Module

ARA-290 Stacking Module

ARA-290 (cibinetide) is the tissue-protective compound with the most genuine clinical development record in the repair group — a completed Phase 2b trial with a met primary endpoint. That makes its stacking discussion unusual here: the single compound has real data, so the honest framing is that combinations dilute rather than build on a known quantity.

ARA-290 Guide at MedibactARA-290 calculatorPeptide Stacking Guide

Educational use only — not medical advice. This page summarizes information reported in published research and community practice for educational purposes. It is not medical advice and not a recommendation to use any compound. Any doses, schedules, or combinations shown are examples of what has been reported, not instructions for you. Many peptides described here are research compounds that are not FDA-approved for the uses discussed and may be investigational or restricted. Effects, risks, and legal status vary; individual needs and results vary. Consult a qualified, licensed healthcare professional before making any decision. Do not use this content to diagnose, treat, or dose yourself.

How to think about stacking ARA-290

  • ARA-290 selectively activates the innate repair receptor, deliberately avoiding the classical EPO receptor that drives red-cell production. That selectivity is its design rationale and means it does not raise haemoglobin the way EPO does.
  • Its mechanism — anti-inflammatory and tissue-protective signaling via a distinct receptor complex — does not overlap BPC-157, TB-500, GHK-Cu or KPV, so combinations here are not class collisions.
  • The Phase 2b trial found 4 mg daily met the primary endpoint while 8 mg did not. More was not better, which is worth carrying into any stack where the temptation is to add.
  • No controlled trial has studied ARA-290 combined with anything.

Combinations in detail

Tissue protection

ARA-290 + BPC-157
Why it is proposed
Innate-repair-receptor signaling alongside BPC-157's angiogenesis and tissue-healing literature — genuinely different mechanisms converging on repair.
What is reported in practice
Reported as separate vials; ARA-290's trial schedule was once daily.
Cautions specific to this combination
ARA-290 has the better evidence of the two, so this pairing adds a less-characterised compound to a better-characterised one. No combination data.

Inflammation focus

ARA-290 + KPV
Why it is proposed
Two anti-inflammatory mechanisms — innate repair receptor activation and alpha-MSH-fragment signaling — approaching inflammation from different directions.
What is reported in practice
Separate vials.
Cautions specific to this combination
Two anti-inflammatory compounds is closer to mechanistic overlap than the other ARA-290 pairings; the receptors differ but the intended endpoint is the same, so additivity is assumed rather than shown.

Repair and remodeling

ARA-290 + GHK-Cu
Why it is proposed
Tissue protection alongside copper-driven matrix remodeling.
What is reported in practice
Separate vials.
Cautions specific to this combination
GHK-Cu adds cumulative copper exposure, a constraint ARA-290 does not carry, and its strongest evidence is topical rather than injected.

What to avoid, and why

  • Escalating amounts on the assumption that more is better — the trial's 8 mg arm did not meet the endpoint that 4 mg did.
  • Expecting EPO-like effects on red-cell count; the molecule is specifically designed not to do that.
  • Treating community protocols as equivalent to the trial protocol, which was 28 days under monitoring.

Related reading

The Peptide Stacking GuideAll stacking pages

Every combination described here is reported practice or mechanism-level reasoning. No controlled trial has studied any of these combinations, and nothing on this page is a personal protocol, a dose recommendation, or medical advice.